Organprotektion Lab
From OpenWetWare
(→Members) |
Current revision (16:30, 26 January 2011) (view source) (→Members) |
||
| (16 intermediate revisions not shown.) | |||
| Line 2: | Line 2: | ||
[[Image:AG_Organprotektion_Wü.png|thumb|Our group in 2007]] | [[Image:AG_Organprotektion_Wü.png|thumb|Our group in 2007]] | ||
| - | ==Anesthetic-induced preconditioning== | + | ==Anesthetic-induced preconditioning and postconditioning== |
| - | Volatile anesthetics not only induce anesthesia, but also render organs resistant against ischemic damage. For example, the magnitude of an experimentally induced myocardial infarct size can be reduced by more than 50% by the administration of volatile anesthetics, even if the administration has been discontinued prior to the ischemic injury (anesthetic-induced preconditioning, APC). These protective effects are also effective in other organ systems; e.g. the brain. APC is as effective as ischemic preconditioning and thus | + | Volatile anesthetics not only induce anesthesia, but also render organs resistant against ischemic damage. For example, the magnitude of an experimentally induced myocardial infarct size can be reduced by more than 50% by the administration of volatile anesthetics, even if the administration has been discontinued prior to the ischemic injury (anesthetic-induced preconditioning, APC). These protective effects are also effective in other organ systems; e.g. the brain. APC is as effective as ischemic preconditioning and thus represent one of the most potent therapeutic strategies of infarct size reduction. Surgery-related temporary ischemia of the heart or the brain can be prevented using APC in the perioperative period.<br> |
| - | However, infarct sparing therapies can often only be applied after the patient’s admission to the hospital. Even in this situation the patient can benefit from the application of volatile anesthetics | + | However, infarct sparing therapies can often only be applied after the patient’s admission to the hospital. Even in this situation the patient can benefit from the application of volatile anesthetics.Recently, it has been described that volatile anesthetics also exert cardioprotective properties when administered after the ischemic injury (anesthetic-induced postconditioning, APOST). This might be of enormous therapeutical implications since myocardial ischemia is often unpredictable.<br> |
| - | The intracellular mechanisms underlying APC are under intense investigation. The projects performed by our group aim to identify triggers, mediators and end-effectors of anesthetic-induced pre- and postconditioning and to characterize their complex intracellular interaction. Given the large incidence of perioperative cardiovascular morbidity and mortality and the incidence of myocardial and cerebral infarction, the results of these projects are of high clinical relevance and might provide a better understanding of the cardioprotective properties of volatile anesthetics. They might help to choose the appropriate and protective | + | The intracellular mechanisms underlying APC and APOST are under intense investigation. The projects performed by our group aim to identify triggers, mediators and end-effectors of anesthetic-induced pre- and postconditioning and to characterize their complex intracellular interaction. Particularly, we focuse on ß1- and ß2-adrenergic receptors and their downstream targets. Given the large incidence of perioperative cardiovascular morbidity and mortality and the incidence of myocardial and cerebral infarction, the results of these projects are of high clinical relevance and might provide a better understanding of the cardioprotective properties of volatile anesthetics. They might help to choose the appropriate and protective anaesthesia regime to alleviate cardiovascular mortality and apoplectic insults in the perioperative period.<br> |
==Members== | ==Members== | ||
'''Head:''' | '''Head:''' | ||
| - | Dr. Markus Lange | + | PD Dr. Markus Lange |
'''Research Fellows:''' | '''Research Fellows:''' | ||
* Dr. Thorsten Smul | * Dr. Thorsten Smul | ||
| - | + | * Dr. Christopher Lotz (currently at UC Los Angeles, USA) | |
| - | * Dr. Christopher Lotz | + | |
* Dr. [[Jan Stumpner]] | * Dr. [[Jan Stumpner]] | ||
| - | * Christoph Blomeyer | + | * Dr. Christoph Blomeyer (currently at Medical College of Wisconsin, Milwaukee, USA) |
| + | * Tobias Tischer-Zeitz | ||
| + | * Dr. Sonja Maisch | ||
| + | * Anja Frank | ||
| - | + | External Collaborator | |
| - | * Dr. | + | * Dr. [[Andreas Redel]], [http://www.uniklinikum-regensburg.de/kliniken-institute/Anaesthesiologie/ Department of Anesthesiology], [http://www.uniklinikum-regensburg.de/ Hospital of the University of Regensburg] |
'''MD Students:''' | '''MD Students:''' | ||
| + | * Tobias Nefzger | ||
* Tobias Tischer-Zeitz | * Tobias Tischer-Zeitz | ||
* Johannes Schmidt | * Johannes Schmidt | ||
* Verena Schnupp | * Verena Schnupp | ||
* Anja Frank | * Anja Frank | ||
| - | * | + | * Joanna Pociej |
| + | * Anna Kellermann | ||
| + | * Nadyia Virstyuk | ||
| + | * Johannes Richl | ||
| + | * Teresa Hilz | ||
| + | * Andreas Beck | ||
| + | * Andreas Neuwirth | ||
| + | * Julia Umminger | ||
| + | * Ulrike Kolar | ||
'''Technician:''' | '''Technician:''' | ||
| - | * | + | * Katerina Pech |
==Methods== | ==Methods== | ||
| Line 37: | Line 48: | ||
* [[Western Blot]] | * [[Western Blot]] | ||
* [[PCR]] | * [[PCR]] | ||
| - | * | + | * ELISA |
==Publications== | ==Publications== | ||
<biblio> | <biblio> | ||
| - | #Paper1 pmid= | + | #Paper1 pmid=19934869 |
| - | #Paper2 pmid= | + | #Paper2 pmid=19596824 |
| - | #Paper3 pmid= | + | #Paper3 pmid=19467889 |
| - | #Paper4 pmid= | + | #Paper4 pmid=19303329 |
| - | #Paper5 pmid= | + | #Paper5 pmid=19167913 |
| - | #Paper6 pmid= | + | #Paper6 pmid=19225392 |
| - | #Paper7 pmid= | + | #Paper7 pmid=18580175 |
| - | #Paper8 pmid= | + | #Paper8 pmid=18518784 |
| - | #Paper9 pmid= | + | #Paper9 pmid=18227289 |
| - | #Paper10 pmid= | + | #Paper10 pmid=18156310 |
| - | #Paper11 pmid= | + | #Paper11 pmid=17563879 |
| - | #Paper12 pmid= | + | #Paper12 pmid=17457146 |
| - | #Paper13 pmid=12457251 | + | #Paper13 pmid=17242104 |
| + | #Paper14 pmid=17006071 | ||
| + | #Paper15 pmid=16931983 | ||
| + | #Paper16 pmid=16766632 | ||
| + | #Paper17 pmid=16399333 | ||
| + | #Paper18 pmid=16217658 | ||
| + | #Paper19 pmid=12457251 | ||
</biblio> | </biblio> | ||
Current revision
Welcome to our OWW homepage! To get further information, please visit our lab homepage!
Contents |
Anesthetic-induced preconditioning and postconditioning
Volatile anesthetics not only induce anesthesia, but also render organs resistant against ischemic damage. For example, the magnitude of an experimentally induced myocardial infarct size can be reduced by more than 50% by the administration of volatile anesthetics, even if the administration has been discontinued prior to the ischemic injury (anesthetic-induced preconditioning, APC). These protective effects are also effective in other organ systems; e.g. the brain. APC is as effective as ischemic preconditioning and thus represent one of the most potent therapeutic strategies of infarct size reduction. Surgery-related temporary ischemia of the heart or the brain can be prevented using APC in the perioperative period.
However, infarct sparing therapies can often only be applied after the patient’s admission to the hospital. Even in this situation the patient can benefit from the application of volatile anesthetics.Recently, it has been described that volatile anesthetics also exert cardioprotective properties when administered after the ischemic injury (anesthetic-induced postconditioning, APOST). This might be of enormous therapeutical implications since myocardial ischemia is often unpredictable.
The intracellular mechanisms underlying APC and APOST are under intense investigation. The projects performed by our group aim to identify triggers, mediators and end-effectors of anesthetic-induced pre- and postconditioning and to characterize their complex intracellular interaction. Particularly, we focuse on ß1- and ß2-adrenergic receptors and their downstream targets. Given the large incidence of perioperative cardiovascular morbidity and mortality and the incidence of myocardial and cerebral infarction, the results of these projects are of high clinical relevance and might provide a better understanding of the cardioprotective properties of volatile anesthetics. They might help to choose the appropriate and protective anaesthesia regime to alleviate cardiovascular mortality and apoplectic insults in the perioperative period.
Members
Head: PD Dr. Markus Lange
Research Fellows:
- Dr. Thorsten Smul
- Dr. Christopher Lotz (currently at UC Los Angeles, USA)
- Dr. Jan Stumpner
- Dr. Christoph Blomeyer (currently at Medical College of Wisconsin, Milwaukee, USA)
- Tobias Tischer-Zeitz
- Dr. Sonja Maisch
- Anja Frank
External Collaborator
MD Students:
- Tobias Nefzger
- Tobias Tischer-Zeitz
- Johannes Schmidt
- Verena Schnupp
- Anja Frank
- Joanna Pociej
- Anna Kellermann
- Nadyia Virstyuk
- Johannes Richl
- Teresa Hilz
- Andreas Beck
- Andreas Neuwirth
- Julia Umminger
- Ulrike Kolar
Technician:
- Katerina Pech
Methods
- in vivo model of acute myocardial infarction in two rodent species
- Western Blot
- PCR
- ELISA
Publications
- Stumpner J, Redel A, Kellermann A, Lotz CA, Blomeyer CA, Smul TM, Kehl F, Roewer N, and Lange M. . pmid:19934869.
- Redel A, Stumpner J, Tischer-Zeitz T, Lange M, Smul TM, Lotz C, Roewer N, and Kehl F. . pmid:19596824.
- Smul TM, Redel A, Stumpner J, Lange M, Lotz C, Roewer N, and Kehl F. . pmid:19467889.
- Lange M, Redel A, Smul TM, Lotz C, Nefzger T, Stumpner J, Blomeyer C, Gao F, Roewer N, and Kehl F. . pmid:19303329.
- Smul TM, Lange M, Redel A, Stumpner J, Lotz CA, Roewer N, and Kehl F. . pmid:19167913.
- Lange M, Redel A, Lotz C, Smul TM, Blomeyer C, Frank A, Stumpner J, Roewer N, and Kehl F. . pmid:19225392.
- Lange M, Smul TM, Redel A, Lotz C, Jazbutyte V, Schnupp V, Roewer N, and Kehl F. . pmid:18580175.
- Kranke P, Redel A, Schuster F, Muellenbach R, and Eberhart LH. . pmid:18518784.
- Redel A, Lange M, Jazbutyte V, Lotz C, Smul TM, Roewer N, and Kehl F. . pmid:18227289.
- Redel A, Jazbutyte V, Smul TM, Lange M, Eckle T, Eltzschig H, Roewer N, and Kehl F. . pmid:18156310.
- Muellenbach RM, Kredel M, Said HM, Klosterhalfen B, Zollhoefer B, Wunder C, Redel A, Schmidt M, Roewer N, and Brederlau J. . pmid:17563879.
- Lange M, Redel A, Roewer N, and Kehl F. . pmid:17457146.
- Lange M, Smul T, Zimmermann P, Kohlenberger R, Roewer N, and Kehl F. . pmid:17242104.
- Smul TM, Lange M, Redel A, Burkhard N, Roewer N, and Kehl F. . pmid:17006071.
- Lange M, Smul TM, Blomeyer CA, Redel A, Klotz KN, Roewer N, and Kehl F. . pmid:16931983.
- Eckle T, Grenz A, Köhler D, Redel A, Falk M, Rolauffs B, Osswald H, Kehl F, and Eltzschig HK. . pmid:16766632.
- Lange M, Roewer N, and Kehl F. . pmid:16399333.
- Golenhofen N, Redel A, Wawrousek EF, and Drenckhahn D. . pmid:16217658.
- Redel A, Baumgartner W, Golenhofen K, Drenckhahn D, and Golenhofen N. . pmid:12457251.
Links
Please visit our lab homepage!
